Five-year biochemical outcome after prostate brachytherapy for hormone-naive men ≤ 62 years of age

International Journal of Radiation Oncology Biology Physics

Volumn 50, Issue 5, 2001, Pages 1253-1257

  Merrick, Gregory S ^a,b   Butler, Wayne M ^a   Lief, Jonathan H ^a,c   Galbreath, Robert W ^a,c  

^a WHEELING HOSPITAL   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^c WHEELING JESUIT UNIVERSITY   (United States)

Author keywords

Biochemical outcome; Brachytherapy; Patient age; Prostate cancer

Indexed keywords

BIOCHEMISTRY; DISEASE CONTROL; IMPLANTS (SURGICAL); PATHOLOGY; RADIOTHERAPY; ULTRASONICS;

BRACHYTHERAPY;

HORMONES;

IODINE 125; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN;

ADENOCARCINOMA; ADULT; ARTICLE; BEAM THERAPY; BRACHYTHERAPY; CONTROLLED STUDY; DEVICE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; IMPLANTATION; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; STATISTICAL ANALYSIS; SURVIVAL; TREATMENT FAILURE; TREATMENT OUTCOME; ULTRASOUND THERAPY;

ADENOCARCINOMA; ADULT; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; LIFE TABLES; MALE; MIDDLE AGED; PALLADIUM; PROSTATIC NEOPLASMS; RADIOISOTOPES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0035425105     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)01539-5     Document Type: Article

References (32)

1. Is brachytherapy comparable with radical prostatectomy and external beam radiation for clinically localized prostate cancer?
2. Palladium-103 brachytherapy for prostate carcinoma
3. Modern prostate brachytherapy: Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up
4. Simultaneous irradiation for prostate cancer: Intermediate results with modern techniques
5. 125iodine implantation for stage T1/T2 prostatic carcinoma
6. Prognostic role of serum prostatic acid phosphatase for 103Pd-based radiation for prostatic carcinoma
7. Five-year biochemical outcome, and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer
8. Five-year biochemical outcome following permanent interstitial brachytherapy for T1-T3 prostate cancer
9. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate
10. Consensus Statement: Guidelines for PSA following radiation therapy
11. The impact of Gleason score accuracy as a criterion for prostate brachytherapy patient selection
12. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43
13. Comparison of seed loading approaches in prostate brachytherapy
14. Modified uniform seed loading for prostate brachytherapy: Rationale, design, and evaluation
15. Potential role of various dosimetric quality indicators in prostate brachytherapy
16. Rectal dosimetric analysis following prostatic conformal brachytherapy
17. The influence of timing on the dosimetric analysis of transperineal ultrasound guided prostatic conformal brachytherapy
18. The effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation
19. The influence of prophylactic dexamethasone on edema following prostate brachytherapy
20. Quality assurance calibration of I-125 rapid strand in a sterile environment
21. Seed fixity in the prostate/periprostatic region following brachytherapy
22. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination
23. Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease
24. Five-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer
25. Age related prostate cancer metastases
26. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediate-term results
27. Young patients with prostate cancer have an outcome justifying their treatment with external beam radiation
28. Prostate-specific antigen after anatomic radical retropubic prostatectomy: Patterns of recurrence and cancer control
29. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer
30. Failure patterns and hazard rates for failure suggest the cure of prostate cancer by external beam radiation
31. Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials